CN116515757A - 基于使用表达增强性基因座来制备抗体的组合物和方法 - Google Patents

基于使用表达增强性基因座来制备抗体的组合物和方法 Download PDF

Info

Publication number
CN116515757A
CN116515757A CN202211606177.7A CN202211606177A CN116515757A CN 116515757 A CN116515757 A CN 116515757A CN 202211606177 A CN202211606177 A CN 202211606177A CN 116515757 A CN116515757 A CN 116515757A
Authority
CN
China
Prior art keywords
rrs
vector
hcf
nucleotide sequence
lcf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202211606177.7A
Other languages
English (en)
Chinese (zh)
Inventor
R·巴布
D·布拉科夫
陈刚
J·P·梵迪
Y·赵
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of CN116515757A publication Critical patent/CN116515757A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Reproductive Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CN202211606177.7A 2016-04-20 2017-04-20 基于使用表达增强性基因座来制备抗体的组合物和方法 Pending CN116515757A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662325400P 2016-04-20 2016-04-20
US62/325,400 2016-04-20
CN201780024557.0A CN109195986B (zh) 2016-04-20 2017-04-20 基于使用表达增强性基因座来制备抗体的组合物和方法
PCT/US2017/028555 WO2017184832A1 (en) 2016-04-20 2017-04-20 Compositions and methods for making antibodies based on use of expression-enhancing loci

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780024557.0A Division CN109195986B (zh) 2016-04-20 2017-04-20 基于使用表达增强性基因座来制备抗体的组合物和方法

Publications (1)

Publication Number Publication Date
CN116515757A true CN116515757A (zh) 2023-08-01

Family

ID=58701851

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780024557.0A Active CN109195986B (zh) 2016-04-20 2017-04-20 基于使用表达增强性基因座来制备抗体的组合物和方法
CN202211606177.7A Pending CN116515757A (zh) 2016-04-20 2017-04-20 基于使用表达增强性基因座来制备抗体的组合物和方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201780024557.0A Active CN109195986B (zh) 2016-04-20 2017-04-20 基于使用表达增强性基因座来制备抗体的组合物和方法

Country Status (15)

Country Link
US (2) US11512144B2 (enExample)
EP (1) EP3445781A1 (enExample)
JP (3) JP7096770B2 (enExample)
KR (2) KR20230098361A (enExample)
CN (2) CN109195986B (enExample)
AR (1) AR109451A1 (enExample)
AU (2) AU2017253241B2 (enExample)
BR (1) BR112018071283A2 (enExample)
CA (1) CA3015389A1 (enExample)
EA (1) EA201892010A1 (enExample)
IL (2) IL314779A (enExample)
MX (2) MX2018012868A (enExample)
SG (2) SG10202010155YA (enExample)
TW (2) TW202415767A (enExample)
WO (1) WO2017184832A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202010155YA (en) * 2016-04-20 2020-11-27 Regeneron Pharma Compositions and methods for making antibodies based on use of expression-enhancing loci
IL275462B1 (en) * 2017-12-22 2025-09-01 Genentech Inc Targeted integration of nucleic acids
CA3123448A1 (en) * 2018-12-21 2020-06-25 Genentech, Inc. Targeted integration of nucleic acids
TWI851703B (zh) * 2019-04-02 2024-08-11 日商中外製藥股份有限公司 標的特異性外源基因的導入方法
JP7720787B2 (ja) * 2019-06-26 2025-08-08 ジェネンテック， インコーポレイテッド 核酸のランダム化された構成標的化組込み
EP4419698A1 (en) 2021-10-18 2024-08-28 Regeneron Pharmaceuticals, Inc. Mammalian cells comprising integrated cas9 genes to produce stable integration sites, and mammalian cells comprising stable integration sites and other sites
AU2022373653A1 (en) 2021-10-18 2024-05-02 Regeneron Pharmaceuticals, Inc. Eukaryotic cells comprising adenovirus-associated virus polynucleotides
TW202330926A (zh) 2021-10-18 2023-08-01 美商再生元醫藥公司 聚核苷酸之受控制轉錄
WO2023122246A1 (en) * 2021-12-22 2023-06-29 Genentech, Inc. Multi-vector recombinase mediated cassette exchange
JPWO2023238949A1 (enExample) * 2022-06-10 2023-12-14
WO2025054526A1 (en) 2023-09-07 2025-03-13 Regeneron Pharmaceuticals, Inc. Production and purification of covalently surface modified adeno-associated virus
WO2025111473A1 (en) 2023-11-21 2025-05-30 Regeneron Pharmaceuticals, Inc. Covalently surface modified adeno-associated virus production by in vitro conjugation, and purification of covalently surface modified adeno-associated virus

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6800457B2 (en) 1998-09-22 2004-10-05 Bristol-Myers Squibb Company Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
US6406863B1 (en) 2000-06-23 2002-06-18 Genetastix Corporation High throughput generation and screening of fully human antibody repertoire in yeast
JP4817657B2 (ja) 2002-05-29 2011-11-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 誘導性の真核生物発現システム
WO2004046340A2 (en) 2002-11-14 2004-06-03 Genentech, Inc. Intron fusion construct and method of using for selecting high-expressing production cell lines
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
CA2646965C (en) 2006-03-24 2016-06-21 Jonathan H. Davis Engineered heterodimeric protein domains
PL2374818T3 (pl) 2006-06-02 2013-05-31 Regeneron Pharma Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6
WO2008079943A2 (en) 2006-12-21 2008-07-03 Smithkline Beecham Corporation Novel methods
US20080216185A1 (en) 2007-01-19 2008-09-04 Invitrogen Corporation Compositions and Methods for Genetic Manipulation and Monitoring of Cell Lines
ES2667863T3 (es) 2007-03-29 2018-05-14 Genmab A/S Anticuerpos biespecíficos y métodos de producción de los mismos
US7771997B2 (en) 2007-06-04 2010-08-10 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
ES2563027T3 (es) 2008-01-07 2016-03-10 Amgen Inc. Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
CN102459603B (zh) * 2009-06-02 2013-11-06 瑞泽恩制药公司 岩藻糖基化缺陷型细胞
MX368932B (es) 2009-06-26 2019-10-22 Regeneron Pharma Anticuerpos biespecificos facilmente aislados con formato de inmunoglobulina original.
JP6091894B2 (ja) 2009-09-16 2017-03-15 ジェネンテック， インコーポレイテッド コイルドコイルおよび／またはテザー含有タンパク質複合体およびその使用
SG178940A1 (en) * 2009-09-18 2012-04-27 Selexis Sa Products and methods for enhanced transgene expression and processing
US9150663B2 (en) 2010-04-20 2015-10-06 Genmab A/S Heterodimeric antibody Fc-containing proteins and methods for production thereof
JP5997154B2 (ja) 2010-08-16 2016-09-28 ノビミューン エスアー 多重特異性多価抗体の生成方法
TW201823460A (zh) 2012-05-29 2018-07-01 美商再生元醫藥公司 生產細胞株增強子
EP2711428A1 (en) * 2012-09-21 2014-03-26 Lonza Biologics plc. Site-specific integration
US20150203591A1 (en) * 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
TWI745610B (zh) 2012-11-14 2021-11-11 美商再生元醫藥公司 重組細胞表面捕捉蛋白質
TWI682941B (zh) * 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
TWI670283B (zh) 2013-12-23 2019-09-01 美商建南德克公司 抗體及使用方法
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
AU2015335921B2 (en) 2014-10-23 2020-06-25 Regeneron Pharmaceuticals, Inc. Novel CHO integration sites and uses thereof
PT3353212T (pt) 2015-09-23 2022-01-05 Regeneron Pharma Anticorpos biespecíficos anti-cd3 otimizados e suas utilizações
SG10202010155YA (en) * 2016-04-20 2020-11-27 Regeneron Pharma Compositions and methods for making antibodies based on use of expression-enhancing loci

Also Published As

Publication number Publication date
CN109195986A (zh) 2019-01-11
MX2018012868A (es) 2019-03-11
TW202415767A (zh) 2024-04-16
EP3445781A1 (en) 2019-02-27
US20190233544A1 (en) 2019-08-01
JP7096770B2 (ja) 2022-07-06
EA201892010A1 (ru) 2019-03-29
IL262266B2 (en) 2025-01-01
IL262266A (en) 2018-11-29
JP2021164479A (ja) 2021-10-14
US11512144B2 (en) 2022-11-29
TWI827531B (zh) 2024-01-01
JP2024023449A (ja) 2024-02-21
KR20230098361A (ko) 2023-07-03
MX2025003852A (es) 2025-05-02
IL262266B1 (en) 2024-09-01
CA3015389A1 (en) 2017-10-26
BR112018071283A2 (pt) 2019-02-12
AU2017253241B2 (en) 2024-07-04
TW201803986A (zh) 2018-02-01
KR102547738B1 (ko) 2023-06-26
CN109195986B (zh) 2023-01-03
JP7781128B2 (ja) 2025-12-05
SG11201807885PA (en) 2018-10-30
AU2024220124A1 (en) 2024-10-17
WO2017184832A1 (en) 2017-10-26
AR109451A1 (es) 2018-12-12
AU2017253241A1 (en) 2018-09-20
US20230130799A1 (en) 2023-04-27
JP2019515666A (ja) 2019-06-13
SG10202010155YA (en) 2020-11-27
KR20180134893A (ko) 2018-12-19
IL314779A (en) 2024-10-01

Similar Documents

Publication Publication Date Title
JP7789143B2 (ja) 発現強化座位の使用に基づく抗体を作製するための組成物および方法
JP7781128B2 (ja) 発現強化座位の使用に基づいた抗体を作製するための組成物および方法
US12503520B2 (en) Compositions and methods for making antibodies based on use of an expression-enhancing locus
JP2025188169A (ja) 発現強化座位の使用に基づいた抗体を作製するための組成物および方法
EA046654B1 (ru) Композиции и способы получения антител, основанные на применении локусов, обеспечивающих повышенную экспрессию

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination